Advertisement

The structure of human cyclooxygenase-2 and selective inhibitors

  • M. F. Browner
Chapter

Abstract

The committed step in the production of prostanoids is the metabolism of arachidonic acid to prostaglandin H2 (PGH2) by the enzyme prostaglandin H2 synthase, also referred to as cyclooxygenase (COX)1. Two COX enzymes have been identified2,3, termed COX-1 and COX-2. The COX-1 protein has been shown to be constitutively expressed in a wide variety of cells, whereas the expression of COX-2 is induced in response to pro-inflammatory stimuli4. It is now well established that non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen, flurbiprofen and naproxen, block the production of prostaglandins by inhibiting the COX enzymes5. More recently, these traditional NSAIDs have been shown to be non-selective, inhibiting both COX-1 and COX-26. A hypothesis derived from these discoveries proposes that the undesirable side effects of classical COX inhibitors results from the inhibition of COX-1, whereas the therapeutic, anti-inflammatory effects result from the inhibition of COX-27.

Keywords

Amino Acid Difference Prostaglandin Endoperoxide Tyrosyl Radical Haem Cofactor Inhibitor Binding Site 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Smith WL, Borgeat P, Fitzpatrick FA. The eicosanoids: Cycloxygenase, lipoxygenase, and epoxygenase pathways. In Vance DE, Vance J, eds., Biochemistry of lipids, lipoproteins and membranes. Elsevier Science Publishers; 1991: 297–325.Google Scholar
  2. 2.
    Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS 10, a phorbol ester tumor promoter-inducible mRNA from swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase. J Biol Chem. 1991; 266: 12866–12872.PubMedGoogle Scholar
  3. 3.
    Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA. 1992; 89: 7384–7388.PubMedCrossRefGoogle Scholar
  4. 4.
    Goppelt-Struebe M. Regulation of Prostaglandin Endoperoxide Synthase (Cyclooxygenase) Isozyme expression. Prostaglandins, Leukotrienes and Essential Fatty Acids. 1995; 52: 213–222.CrossRefGoogle Scholar
  5. 5.
    Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol. 1971; 231: 232–235.PubMedGoogle Scholar
  6. 6.
    Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of non-steroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA. 1993; 90: 11693–11697.PubMedCrossRefGoogle Scholar
  7. 7.
    Vane J. Towards a better aspirin. Nature. 1994; 367: 215–216.PubMedCrossRefGoogle Scholar
  8. 8.
    Verlinde C, Hol W. Structure-based drug design: Progress, results and challenges. Structure. 1994; 2: 577–587.PubMedCrossRefGoogle Scholar
  9. 9.
    Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. The structure of human cyclooxygenase-2: Conservation and flexibility of the NSAID binding site. 1996; submitted.Google Scholar
  10. 10.
    Barnett J, Chow J, Ives D et al. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochem Biophys Acta. 1994; 1209: 130–139.PubMedCrossRefGoogle Scholar
  11. 11.
    Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 1994; 367: 243–249.PubMedCrossRefGoogle Scholar
  12. 12.
    Loll PJ, Picot D, Ekabo O, Garavito RM. Synthesis and use of iodinated non-steroidal anti-inflammatory drug analogs as crystallographic probes of the prostaglandin H2 cyclooxygenase active site. Biochemistry. 1996; 35: 7330–7340.PubMedCrossRefGoogle Scholar
  13. 13.
    Kurumbail RG, Stevens AM, Gierse JK et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996; 384: 644–648.PubMedCrossRefGoogle Scholar
  14. 14.
    Smith WL, Eling TE, Kulmacz RJ, Marnett LJ, Tsai, sA. Tyrosyl radicals and their role in hydroperoxide dependent activation and inactivation of prostaglandin endoperoxide synthase. Biochemistry. 1992; 31: 3–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Tsai A, Kulmacz RJ, Palmer G. Spectroscopic evidence for reaction of prostaglandin H synthase-1 tyrosyl radical with arachidonic acid. J Biol Chem. 1995; 270: 10503–10508.PubMedCrossRefGoogle Scholar
  16. 16.
    Shimokawa T, Kulmacz RJ, Dewitt DL, Smith WL. Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis. J Biol Chem. 1990; 265: 20073–20076.PubMedGoogle Scholar
  17. 17.
    Lassmann G, Odenwaller R, Curtis JF, DeGray JA, Mason RP, Marnett LJ, Eling TE. Electron spin resonance investigation of tyrosyl radicals of prostaglandin H synthase: Relation to enzyme catalysis. J Biol Chem. 1991; 266: 20045–20055.PubMedGoogle Scholar
  18. 18.
    Tazawa R, Xu XM, Wu KK, Wang LH. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun. 1994; 203: 190–199.PubMedCrossRefGoogle Scholar
  19. 19.
    Mancini JA, Riendeau D, Falgueyret, J-P, Vickers PJ, O’Neill GP. Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by non-steroidal anti-inflammatory drugs containing a carboxylic acid moiety. J Biol Chem. 1995; 270: 29372–29377.PubMedCrossRefGoogle Scholar
  20. 20.
    Bhattacharyya DK, Lecomte M, Rieke CJ, Garavito RM, Smith WL. Involvement of arginine 120, glutamate 524, and tyrosine 355 in binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide synthase-1. J Biol Chem. 1996; 271: 2179–2184.PubMedCrossRefGoogle Scholar
  21. 21.
    DeWitt DL, El-Harith EA, Kraemer SA, Andrews MJ, Yao EF, Armstrong RL, Smith WL. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J Bio Chem. 1990; 265: 5192–5198.Google Scholar
  22. 22.
    Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nature Struct Biol. 1995; 2: 637–642.PubMedCrossRefGoogle Scholar
  23. 23.
    Copeland RA, Williams JM, Giannaras J et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA. 1994; 91: 11202–11206.PubMedCrossRefGoogle Scholar
  24. 24.
    Nicholls A, Sharp K, Honig B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins. 1991; 11: 281–296.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1998

Authors and Affiliations

  • M. F. Browner

There are no affiliations available

Personalised recommendations